Action Sanofi - SAN

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

83,22

Prix Achat

82,82

Prix Vente

83,70

Volume échangé

4 813 462

82,84 Fourchette du Jour 84,04

82,29 Plage de 52 semaines 110,88

Cap du marché

104,245B

Clôture Veille

83,12

Ouverture

83,49

Dernière Transaction

83.22

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

2 339 305

Actions en circulation

1 252 640 466

Rendement du Dividende

4.71%

Ratio Cours sur Bénéfices

18,69

Bénéfice par action (BPA)

4,44

Chiffre d'affairess

46,11B

Bénéfice net

5,56B

Secteur

Health & Allied Services,nec

Industrie

Pharmaceutical Preparations

Site Web

www.sanofi.com

Siège social

Paris, Paris, Fra

Fondé

1994

Sanofi est coté dans le secteur Health & Allied Services de la Euronext avec le ticker SAN. Le dernier cours de clôture d'Sanofi était de 83,12 €. Au cours de la dernière année, les actions de Sanofi ont été négociées dans une fourchette de prix de 82,29 € à 110,88 €.

Sanofi compte actuellement 1 252 640 466 actions en circulation. La capitalisation boursière d'Sanofi est de 104,12 € milliard. Sanofi a un ratio cours/bénéfice (ratio PE) de 18.69.

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde...

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Dupixent approved in the US as...

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval...

Press release: Sanofi successfully prices €1.5 billion bond issue

Press release: Sanofi successfully prices €1.5 billion bond issue Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025...

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires Sanofi place 1,5 milliard d’euros d’emprunts obligataires ...

Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with...

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients...

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps...

Sanofi: Information concerning the total number of voting rights and shares - May 2025

Sanofi: Information concerning the total number of voting rights and shares - May 2025 Information concerning the total number of voting rights...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-3.73	-4.28982173663	86.95	87.44	82.29	2156438	84.81137596	DE
4	-10.04	-10.7656015441	93.26	93.73	82.29	2159219	87.43528731	DE
12	-9.17	-9.9253165927	92.39	98.36	82.29	2339305	90.53320689	DE
26	-7.67	-8.43877214215	90.89	110.88	82.29	2047911	96.70932628	DE
52	-3.8	-4.36681222707	87.02	110.88	82.29	1767326	96.57183822	DE
156	-10.9	-11.580960476	94.12	110.88	76.45	1682824	92.87735044	DE
260	-9.78	-10.5161290323	93	110.88	74.92	1826081	90.85520102	DE

SAN - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is 83,22 €

How many Sanofi shares are in issue?

Sanofi has 1 252 640 466 shares in issue

What is the market cap of Sanofi?

The market capitalisation of Sanofi is EUR 104,12B

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of 82,29 € to 110,88 € during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 18,69

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 2,25

What is the reporting currency for Sanofi?

Sanofi reports financial results in EUR

What is the latest annual turnover for Sanofi?

The latest annual turnover of Sanofi is EUR 46,11B

What is the latest annual profit for Sanofi?

The latest annual profit of Sanofi is EUR 5,56B

What is the registered address of Sanofi?

The registered address for Sanofi is 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
BIOSBiosenic	0,0029 € (38,10%)	25,5M
ORDDSOrdissimo	0,006 € (36,36%)	51,75k
ETLEutelsat Communications	3,715 € (30,81%)	24,07M
ALTAILighton	10,95 € (26,01%)	204,93k
ALALOAcheterLouerFR	0,001 € (25,00%)	177,41M
VALDSValbiotis SA	0,0001 € (-75,00%)	902,06k
BNBSTonner Drones	0,006 € (-25,00%)	1,49M
ALODYOdyssee Technologies	40,10 € (-19,32%)	18,86k
CHSRChausseria	7,00 € (-17,65%)	2
MLAAHAmatheon Agri Holding NV	0,028 € (-15,15%)	414,5k
ALALOAcheterLouerFR	0,001 € (25,00%)	177,41M
ALHPIHopium SA	0,0003 € (0,00%)	165,92M
BCPBanco Comercial Portugues SA	0,662 € (3,63%)	160,13M
ALEUPEuroplasma	0,0064 € (-13,51%)	70,74M
ALNEVNeovacs	0,0024 € (0,00%)	66,1M

Forums

Afficher les forums

Sanofi - Fin de la correction ?	107
Sanofi-Aventis	102
Sanofi qu''est ce que tu attends ?	10
Warrant: SANOFI-AVENTIS	0
Warrants: SANOFI	0
Warrants : SANOFI AVENTIS	0
SANOFI	0
SANOFI-AVENTIS	1
Sanofi-Aventis	38

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sanofi (SAN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Sanofi

SAN Dernières nouvelles

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press release: Sanofi successfully prices €1.5 billion bond issue

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Press release: Sanofi successfully prices €1.5 billion bond issue

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Sanofi: Information concerning the total number of voting rights and shares - May 2025

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press release: Sanofi successfully prices €1.5 billion bond issue

Press release: Sanofi successfully prices €1.5 billion bond issue

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

SAN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Sanofi (SAN) Cours

Sanofi (SAN)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Sanofi

SAN Dernières nouvelles

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press release: Sanofi successfully prices €1.5 billion bond issue

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Press release: Sanofi successfully prices €1.5 billion bond issue

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Sanofi: Information concerning the total number of voting rights and shares - May 2025

Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press release: Sanofi successfully prices €1.5 billion bond issue

Press release: Sanofi successfully prices €1.5 billion bond issue

Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

SAN - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités